Ru Yuan Chua

Ru Yuan Chua

Auto-generated profile, based on publicly available information

Ru Yuan Chua

Healthy Longevity Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2024 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
YYYu Fung Yau
Yu Fung Yau
ICIrwin Cheah
Irwin Cheah
RMRathi Mahendran
Rathi Mahendran
RTRichard My Tang
Richard My Tang
RCRu Yuan Chua
Ru Yuan Chua
BHBarry Halliwell
Barry Halliwell
Background: Dementia, particularly Alzheimer's disease, is a major healthcare challenge in ageing societies. Objective: This study aimed to investigate the efficacy and safety of a dietary compound, ergothioneine, in delaying cognitive decline in older individuals. Methods: Nineteen subjects aged 60 or above with mild cognitive impairment were recruited for this double-blinded, randomized, and placebo-controlled study (ClinicalTrials.gov identifier: NCT03641404, registration date: 19/08/2018). Subjects received either ergothioneine (25 mg per capsule) or a placebo, taken 3 times a week for one year. The whole blood profile, markers of renal and liver functions, neurocognitive performance, plasma levels of ergothioneine and its metabolites, and plasma biomarkers related to neurodegeneration were measured across the study. Results: Ergothioneine intake did not alter clinical safety markers (blood counts, kidney and liver function) throughout the study, further validating its safety for human consumption. Subjects receiving ergothioneine demonstrated improved performance in assessment of learning ability and stabilized plasma levels of neurofilament light chain, compared with the placebo group, which saw no improvement in cognitive assessments and a significant increase in neurofilament light chain levels. Conclusions: Prolonged intake of ergothioneine showed no toxicity in elderly people. Enhanced Rey Auditory Verbal Learning Test performance and stabilized neurofilament light chain levels suggest improvements in memory and learning abilities and a deceleration of neuronal damage, respectively. Our results add to existing data that ergothioneine is safe for extended consumption and may hold the potential to delay cognitive decline in elderly adults.

1 January 2022 in Journal of Psychiatric Research
Verified
Journal Article
Closed access
LLLing-Yun Liu
Ling-Yun Liu
Yanxia LuYanxia Lu
Yanxia Lu
LSLiang Shen
Liang Shen
CLChun-Bo Li
Chun-Bo Li
JYJin-Tai Yu
Jin-Tai Yu
Lei FengLei Feng
Lei Feng

9 July 2024 in medRxiv
Verified
Preprint
Open access
PDF file
YYYu Fung Yau
Yu Fung Yau
ICIrwin Cheah
Irwin Cheah
RMRathi Mahendran
Rathi Mahendran
RTRichard M.Y. Tang
Richard M.Y. Tang
RCRu Yuan Chua
Ru Yuan Chua
BHBarry Halliwell
Barry Halliwell
Background and objective Dementia, particularly Alzheimer’s disease, is a major healthcare challenge in ageing societies. Therefore, this study aimed to investigate the efficacy and safety of a dietary compound, ergothioneine, in delaying cognitive decline in elderly individuals. Design, intervention and measurements Nineteen subjects aged 60 or above with mild cognitive impairment were recruited for this double-blinded, randomized, and placebo- controlled study. Subjects received either ergothioneine (25mg per capsule) or a placebo, taken 3 times a week for one year. The whole blood profile, markers of renal and liver functions, neurocognitive performance, plasma levels of ergothioneine and its metabolites, and plasma biomarkers related to neurodegeneration were measured across the study. Result Ergothioneine intake did not alter clinical safety markers (blood counts, kidney and liver function) throughout the study, further validating its safety for human consumption. Subjects receiving ergothioneine demonstrated improved performance in assessment of learning ability and stabilized plasma levels of neurofilament light chain, compared with placebo group which saw no improvement in cognitive assessments and a significant increase in neurofilament light chain. Conclusion Prolonged intake of ergothioneine showed no toxicity in elderly individuals. Enhanced Rey Auditory Verbal Learning Test performance and stabilized neurofilament light chain levels suggest improvements in memory and learning abilities, alongside a deceleration of neuronal damage. Our results add to existing data that ergothioneine is safe for extended consumption and may hold the potential to delay cognitive decline in the elderly.